Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of nine systematic review(s)/meta-analysis(es). ^[1-9]
• At week 26, 79% of participants treated with TransCon parathyroid hormone (PTH) achieved the composite primary efficacy endpoint of maintaining normal albumin-adjusted serum calcium levels, independence from conventional therapy, and no increase in study drug, compared to 5% in the placebo group (p < 0.0001).
• TransCon PTH significantly improved health-related quality of life, as indicated by the surface factor (SF)-36 Physical Functioning subscale (p = 0.0347) and all key secondary endpoint the Hypoparathyroidism Patient Experience Scales (HPES) domain scores (all p < 0.01), showing enhanced well-being and reduced hypoparathyroidism-related symptoms. 4. 93% of participants on TransCon PTH achieved independence from conventional therapy, with no comparable data provided for the placebo group.
• The most common adverse events for tralokinumab included nasopharyngitis, respiratory events, and atopic dermatitis, with no significant difference in the overall incidence of adverse events compared to placebo (randomized controlled trials (RCTs) (odds ratio (OR)) = 1.00, 95% relative risk (RR) 9.50, 95 % confidence interval (CI) 2.31-39.03 (CI): 0.85-1.18, P = 1.00).
• Tralokinumab was well tolerated, though there was an increased risk of conjunctivitis compared to placebo, and no significant short-term safety concerns were identified, although long-term safety evidence remains uncertain.
• Tralokinumab was evaluated in both pediatric and adult populations with moderate-to-severe atopic dermatitis (TCS). In children and adolescents, the drug's efficacy and safety were assessed, showing significant improvements in clinical outcomes, while adults also demonstrated notable benefits from treatment. No specific subgroup analyses regarding age, gender, or comorbidities were reported in the reviewed studies.